Synthio Labs
Category: Voice / Speech AI
Synthio Labs is a clinical-grade voice AI company building AI agents for life sciences customer engagement, focusing on automating compliance-driven interactions and enhancing patient engagement. Synthio Labs was founded in 2024. The company is led by Supreet Deshpande. Based in San Francisco, United States. Team size: 8-15. Total funding raised: $5.5 million. Latest round: Seed round. Key investors include Elevation Capital, 1984 Ventures, Peak XV Partners, Y Combinator.
- Founded
- 2024
- Headquarters
- San Francisco, United States
- Team size
- 8-15
- Total funding
- $5.5 million
Value proposition
Delivers clinical-grade AI interactions for compliance conversations, rapid patient outreach (e.g., 5,000+ eczema patients reached in 48 hours), and scalable omnichannel engagement tailored for clinical and regulatory requirements
Products and solutions
Jarvis: Clinical-grade Voice AI copilot for pharma field teams, Ather: Multimodal AI engine for omnichannel engagement with physicians and patients, Simulation Studio: Platform for generating high-fidelity digital twins of clinicians and patients for research
Unique value
First AI Medical Expert for Pharma GTM teams, integrating Voice AI with clinical compliance and patient engagement
Target customer
Pharmaceutical companies, healthcare providers, and life sciences organizations requiring AI-driven engagement with clinicians and patients
Industries served
Pharmaceuticals, Life Sciences, Healthcare
Technology advantage
Proprietary AI Operating System unifying three platforms; leverages generative AI for life sciences GTM (CEO's prior McKinsey expertise)
How they differentiate
Synthio Labs specializes in clinical-grade voice AI tailored for life sciences engagement, offering conversational platforms specifically designed for interactions between life sciences organizations, clinicians, and patients. Competitors are more general B2B tools.
Main competitors
Voice AI platforms for healthcare, Traditional pharma engagement tools, General B2B voice AI solutions
Key partnerships
Elevation Capital (lead seed investor), 1984 Ventures, Peak XV Partners, Y Combinator (accelerator), Enterprise life sciences clients (US/Europe)
Notable customers
Global top-10 pharma companies, Leading D2C healthcare brands
Major milestones
Raised $5.5M seed funding (November 2025), Launched AI medical expert platform (April 2025), Joined Y Combinator accelerator program (2024), Scaling enterprise deployments across US and Europe
Growth metrics
Reached 5,000+ eczema patients in 48 hours through AI-powered engagement; early adopters include multiple global top-10 pharma companies
Market positioning
Positioned as a niche AI solution for the life sciences industry, focusing on stakeholder engagement through voice AI technology
Geographic focus
Primarily U.S.-based with global reach in the life sciences sector
Patents and IP
No public patents listed in recent searches; focus on trade secrets and IP around AI workflow integration in regulated healthcare environments
About Supreet Deshpande
Over a decade at the intersection of AI/ML and life sciences, delivering AI solutions across the pharmaceutical value chain. Previously led 'Gen AI for Life Sciences' initiatives at McKinsey & Company, and worked at JPMorgan Chase & Co., ZS, and Winkl A Good Creator Co.
Official website: https://synthiolabs.com